Abstract
Current therapy for acute myeloid leukaemia (AML) is suboptimal with a high incidence of relapse. There is strong evidence that constitutive phosphoinositide 3-kinase (PI3K) activity plays a significant role in the pathophysiology of AML. PI3K products are derived from the activity of a number of PI3K catalytic isoforms (class I, II and III) but the relative contribution of these enzymes in AML remains unknown. As non-isoform-selective inhibitors of PI3K such as LY294002 may produce unwanted toxicity to normal tissues, we have investigated the role of the leukocyte-restricted p110δ PI3K isoform in 14 cases of AML. p110δ was detected in all cases whereas the expression levels of the other class I PI3Ks varied more widely, and were often undetectable. The p110δ-selective compound IC87114 inhibited constitutive phosphorylation of the PI3K target Akt/PKB and reduced cell number to a mean of 66±5% (range 14–88%). In eight cases, the combination of IC87114 and VP16 (a topoisomerase II inhibitor) was synergistic in reducing viable cell number, and was associated with a reduction in constitutive NF-κB activity. IC87114 did not have direct adverse effects or enhance the activity of VP16 on the proliferation and survival of normal haemopoietic progenitors. Overall, our results identify the p110δ isoform as a potential therapeutic target in AML and support a clinical approach to use isoform-selective over broad-spectrum PI3K inhibitors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aggerholm A, Gronbaek K, Guldberg P, Hokland P . (2000). Eur J Haematol 65: 109–113.
Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C et al. (2004). Nature 431: 1007–1011.
Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, Poggi V et al. (2005). Blood 106: 1400–1406.
Bayascas JR, Alessi DR . (2005). Mol Cell 18: 143–145.
Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C et al. (2005). Blood 107: 642–650.
Bousquet M, Recher C, Queleen C, Demur C, Payrastre B, Brousset P . (2005). Br J Haematol 131: 411–413.
Brennan P, Babbage JW, Burgering BM, Groner B, Reif K, Cantrell DA . (1997). Immunity 7: 679–689.
Brognard J, Clark AS, Ni Y, Dennis PA . (2001). Cancer Res 61: 3986–3997.
Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J et al. (2005). Nat Med 11: 936–943.
Cantley LC . (2002). Science 296: 1655–1657.
Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW et al. (1997). J Biol Chem 272: 19236–19241.
Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, Ko YW et al. (2003). Br J Haematol 122: 454–456.
Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A et al. (2002). J Exp Med 196: 753–763.
Cornillet-Lefebvre P, Cuccuini W, Bardet V, Tamburini J, Gillot L, Ifrah N et al. (2005). Leukemia 20: 374–376.
Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ . (2000a). Curr Biol 10: 1201–1204.
Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW et al. (2000b). Mol Cell Biol 20: 9138–9148.
Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M . (2004). Cancer Treat Rev 30: 193–204.
Fruman DA . (2004). Biochem Soc Trans 32: 315–319.
Grandage VL, Gale RE, Linch DC, Khwaja A . (2005). Leukemia 19: 586–594.
Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. (2001). Blood 98: 2301–2307.
Hande KR . (1998). Eur J Cancer 34: 1514–1521.
Hayakaa M, Kaizawa H, Kawaguchi KI, Matsuda K, Ishikawa N, Koizumi T et al. (2002) (Patent number: US 6403588 B1).
Hill K, Welti S, Yu J, Murray JT, Yip SC, Condeelis JS et al. (2000). J Biol Chem 275: 3741–3744.
Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE et al. (2005). Nat Med 11: 507–514.
Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, Carpino N et al. (2002). Mol Cell Biol 22: 8580–8591.
Kang S, Bader AG, Zhao L, Vogt PK . (2005). Cell Cycle 4: 578–581.
Kaspers GJ, Veerman AJ . (2003). Recent Results Cancer Res 161: 196–220.
Kelly LM, Gilliland DG . (2002). Annu Rev Genomics Hum Genet 3: 179–198.
Knight ZA, Chiang GG, Alaimo PJ, Kenski DM, Ho CB, Coan K et al. (2004). Bioorg Med Chem 12: 4749–4759.
Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T . (2004). Leukemia 18: 1438–1440.
Luo J, Manning BD, Cantley LC . (2003a). Cancer Cell 4: 257–262.
Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K et al. (2003b). Leukemia 17: 1–8.
Medema RH, Kops GJ, Bos JL, Burgering BM . (2000). Nature 404: 782–787.
Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK et al. (2003). Leukemia 17: 995–997.
Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H et al. (2005). Leukemia 19: 1361–1366.
Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA et al. (1994). Blood 83: 1603–1611.
Nicholson KM, Anderson NG . (2002). Cell Signal 14: 381–395.
Odero MD, Zeleznik-Le NJ, Chinwalla V, Rowley JD . (2000). Genes Chromosomes Cancer 29: 333–338.
Okkenhaug K, Bilancio A, Emery JL, Vanhaesebroeck B . (2004). Biochem Soc Trans 32: 332–335.
Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E et al. (2002). Science 297: 1031–1034.
Okkenhaug K, Vanhaesebroeck B . (2003). Nat Rev Immunol 3: 317–330.
Parsons R . (2004). Semin Cell Dev Biol 15: 171–176.
Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG . (2004). J Immunol 173: 2236–2240.
Robertson AJ, Jackson S, Kenche V, Yaip C, Parbaharan H, Thompson P . (2001). International Patent Application (Patent Number: WO 0153266 A1).
Roche S, Koegl M, Courtneidge SA . (1994). Proc Natl Acad Sci USA 91: 9185–9189.
Sadhu C, Dick K, Treiberg J, Sowell CG, Kesicki EA, Oliver A . (2001). International Patent Application (Patent Number: WO 0181346 A2).
Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE . (2003). J Immunol 170: 2647–2654.
Samuels Y, Velculescu VE . (2004). Cell Cycle 3: 1221–1224.
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). Science 304: 554.
Sargent JM . (2003). Recent Results Cancer Res 161: 13–25.
Sawyer C, Sturge J, Bennett DC, O'Hare MJ, Allen WE, Bain J et al. (2003). Cancer Res 63: 1667–1675.
Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C et al. (1999). Nat Genet 21: 99–102.
Simpson L, Parsons R . (2001). Exp Cell Res 264: 29–41.
Stirewalt DL, Radich JP . (2003). Nat Rev Cancer 3: 650–665.
Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F et al. (2005). Blood 106: 1063–1066.
Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD . (1997a). Trends Biochem Sci 22: 267–272.
Vanhaesebroeck B, Waterfield MD . (1999). Exp Cell Res 253: 239–254.
Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ et al. (1997b). Proc Natl Acad Sci USA 94: 4330–4335.
Vazquez F, Ramaswamy S, Nakamura N, Sellers WR . (2000). Mol Cell Biol 20: 5010–5018.
Vivanco I, Sawyers CL . (2002). Nat Rev Cancer 2: 489–501.
Wantzin GL, Killmann SA . (1977). Eur J Cancer 13: 647–655.
Warner JK, Wang JC, Hope KJ, Jin L, Dick JE . (2004). Oncogene 23: 7164–7177.
Watts MJ, Somervaille TC, Ings SJ, Ahmed F, Khwaja A, Yong K et al. (2002). Br J Haematol 118: 117–123.
West KA, Castillo SS, Dennis PA . (2002). Drug Resist Updat 5: 234–248.
Wymann MP, Zvelebil M, Laffargue M . (2003). Trends Pharmacol Sci 24: 366–376.
Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M . (2003). Blood 102: 972–980.
Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M et al. (2004). Leukemia 18: 267–275.
Acknowledgements
CB holds a FEBS postdoctoral training grant at the Ludwig Institute for Cancer Research. VLG is supported by the Kay Kendall Leukaemia Fund. Research in the laboratory of BV is supported by the Ludwig Institute for Cancer Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Billottet, C., Grandage, V., Gale, R. et al. A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25, 6648–6659 (2006). https://doi.org/10.1038/sj.onc.1209670
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209670
Keywords
This article is cited by
-
PI3K inhibitors are finally coming of age
Nature Reviews Drug Discovery (2021)
-
Associations of high-altitude polycythemia with polymorphisms in PIK3CD and COL4A3 in Tibetan populations
Human Genomics (2018)
-
Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer
Cellular Oncology (2017)
-
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
Molecular and Cellular Therapies (2015)
-
Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency
Nature Immunology (2014)